ArticleIJID regions2026
Seroprevalence of measles immunoglobulin G antibodies in Bahrain: A cross-sectional study using fever and rash surveillance data (2021-2025).
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Measles remains a public health challenge despite effective vaccines; recent declines in coverage led to resurgent outbreaks worldwide. This study aims to estimate measles immunoglobulin (Ig)G seroprevalence in Bahrain's population and identify immunity gaps using serological data from the national fever and rash surveillance system. Methods: We analyzed fever and rash surveillance data from Bahrain (2021-2025). Suspected measles cases were tested for measles IgG antibodies. Seroprevalence was stratified by age, nationality, vaccination status, and governorate. Overall prevalence was age-adjusted, and differences in seropositivity were tested using chi-square tests. Results: Among 1280 patients, the overall seroprevalence of measles IgG was 81.6% (95% confidence interval: 79.3-83.7%). Seropositivity differed between Bahrainis and non-Bahrainis (82.6% vs 77.3%; Conclusion: Bahrain's age-adjusted measles seroprevalence is within herd immunity thresholds. However, vulnerabilities exist among those aged less than 18 months and non-Bahrainis. Sustained high measles, mumps, and rubella vaccine coverage and enhanced surveillance are important in maintaining measles elimination status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.